Insilico's AI-designed drug shows 3-4 years of biological age reversal in Phase IIa trial
Kyrannio · x · 2026-10-05
- Rentosertib, discovered and designed by Insilico Medicine's AI (target TNIK identified by AI, molecule designed by generative AI), originally developed for idiopathic pulmonary fibrosis, produced a striking secondary result in humans.
- In a 42-patient Phase IIa trial, all 6 proteomic aging clocks measured patients as biologically younger after treatment.
- The strongest regimen showed roughly 3-4 years of predicted biological age reversal after just four weeks, with one clock indicating as much as 6 years.
- A notable data point for the "AI will solve aging" narrative, though it is a secondary analysis in Phase IIa, not a primary endpoint.
Related event: AI-Designed Drug Shows 3-4 Years of Biological Age Reversal in Human Trial(3 posts)→
More from Apps
- First-principles thinking distilled into a Claude Skill that stress-tests your PRD — blaizedsouza · 2026-10-05
- Shoppers use AI buying assistant Muse to skip Amazon, Shopify CEO Tobi Lütke takes note — jeff_weinstein · 2026-10-05
- Muse agent gets kid's prescription filled in 65 minutes, beating 5pm cutoff — armand_ruiz · 2026-10-05
- User lets AI agent audit his insurance policies and finds real annual savings — Scobleizer · 2026-10-05
- AI fiction app dev: the future is scripted emergent game design, not chat — LaillaElgohary · 2026-10-05
- Face-Hugger: A Hugging Face indexer that analyzed 1.2M+ files to fix bad search — RagingRectangle · 2026-10-05